Natera Validates Latitude Test for Colorectal Cancer Detection
Event summary
- Natera published clinical validation of its Latitude tissue-free MRD test in colorectal cancer, analyzed from 1,230 timepoints across 195 patients.
- The study showed high sensitivity (84.4%) and specificity (97.2% sample-level, 92.1% patient-level), with a median lead time of 4.6 months ahead of radiographic recurrence.
- MRD-positivity was associated with worse outcomes and clear predictive value for adjuvant chemotherapy benefit in high-risk stage II and III patients.
- Latitude is a methylation-based test detecting circulating tumor DNA without the need for tumor tissue, complementing Natera’s Signatera test.
The big picture
Natera’s validation of the Latitude test underscores its strategic push into tissue-free molecular residual disease detection, a growing segment in precision oncology. The high sensitivity and specificity metrics position Latitude as a strong contender in the CRC diagnostics space, potentially expanding Natera’s market reach beyond its existing tumor-informed Signatera test. The study’s robust data could accelerate regulatory approvals and adoption among clinicians.
What we're watching
- Regulatory Approval
- Whether CMS’s MolDX program will approve Latitude based on the validation study results.
- Market Expansion
- The pace at which Natera can expand Latitude to additional cancer indications beyond colorectal cancer.
- Competitive Positioning
- How Latitude’s performance metrics will position it against existing and emerging tfMRD tests in the market.
Related topics